Annual EBITDA
-$36.08 M
+$937.00 K+2.53%
31 December 2023
Summary:
Kala Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization is currently -$36.08 million, with the most recent change of +$937.00 thousand (+2.53%) on 31 December 2023. During the last 3 years, it has risen by +$58.74 million (+61.95%). KALA annual EBITDA is now -129.12% below its all-time high of -$15.75 million, reached on 31 December 2015.KALA EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$7.47 M
+$588.00 K+7.30%
30 September 2024
Summary:
Kala Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization is currently -$7.47 million, with the most recent change of +$588.00 thousand (+7.30%) on 30 September 2024. Over the past year, it has dropped by -$306.00 thousand (-4.27%). KALA quarterly EBITDA is now -124.36% below its all-time high of $30.67 million, reached on 30 September 2022.KALA Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$32.91 M
-$306.00 K-0.94%
30 September 2024
Summary:
Kala Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization is currently -$32.91 million, with the most recent change of -$306.00 thousand (-0.94%) on 30 September 2024. Over the past year, it has increased by +$7.27 million (+18.10%). KALA TTM EBITDA is now -1305.08% below its all-time high of -$2.34 million, reached on 30 June 2023.KALA TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
KALA EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +2.5% | -4.3% | +18.1% |
| 3 y3 years | +62.0% | +71.0% | +71.8% |
| 5 y5 years | +42.8% | +64.0% | +62.8% |
KALA EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +72.9% | -124.4% | +83.5% | -1305.1% | +75.8% |
| 5 y | 5 years | at high | +72.9% | -124.4% | +83.5% | -1305.1% | +75.8% |
| alltime | all time | -129.1% | +72.9% | -124.4% | +83.5% | -1305.1% | +75.8% |
Kala Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$7.47 M(-7.3%) | -$32.91 M(+0.9%) |
| June 2024 | - | -$8.06 M(-21.6%) | -$32.60 M(-2.6%) |
| Mar 2024 | - | -$10.29 M(+45.1%) | -$33.46 M(-7.3%) |
| Dec 2023 | -$36.08 M(-2.5%) | -$7.09 M(-1.1%) | -$36.08 M(-10.2%) |
| Sept 2023 | - | -$7.17 M(-19.7%) | -$40.18 M(+1615.6%) |
| June 2023 | - | -$8.92 M(-30.9%) | -$2.34 M(-87.8%) |
| Mar 2023 | - | -$12.90 M(+15.4%) | -$19.17 M(-48.2%) |
| Dec 2022 | -$37.02 M(-72.2%) | -$11.19 M(-136.5%) | -$37.02 M(-47.9%) |
| Sept 2022 | - | $30.67 M(-219.1%) | -$71.11 M(-44.3%) |
| June 2022 | - | -$25.75 M(-16.2%) | -$127.58 M(-6.2%) |
| Mar 2022 | - | -$30.75 M(-32.1%) | -$135.98 M(+2.0%) |
| Dec 2021 | -$133.25 M(+40.5%) | -$45.28 M(+75.5%) | -$133.25 M(+14.2%) |
| Sept 2021 | - | -$25.80 M(-24.5%) | -$116.67 M(+0.2%) |
| June 2021 | - | -$34.15 M(+21.9%) | -$116.45 M(+12.8%) |
| Mar 2021 | - | -$28.02 M(-2.4%) | -$103.25 M(+8.9%) |
| Dec 2020 | -$94.83 M | -$28.70 M(+12.3%) | -$94.83 M(+10.6%) |
| Sept 2020 | - | -$25.57 M(+22.0%) | -$85.71 M(+5.9%) |
| June 2020 | - | -$20.95 M(+6.9%) | -$80.91 M(-0.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | -$19.60 M(+0.1%) | -$81.50 M(-4.1%) |
| Dec 2019 | -$85.02 M(+34.8%) | -$19.58 M(-5.7%) | -$85.02 M(-3.9%) |
| Sept 2019 | - | -$20.77 M(-3.6%) | -$88.45 M(+6.8%) |
| June 2019 | - | -$21.55 M(-6.8%) | -$82.78 M(+9.7%) |
| Mar 2019 | - | -$23.12 M(+0.5%) | -$75.44 M(+19.6%) |
| Dec 2018 | -$63.07 M(+55.5%) | -$23.01 M(+52.4%) | -$63.07 M(+24.2%) |
| Sept 2018 | - | -$15.10 M(+6.3%) | -$50.79 M(+11.7%) |
| June 2018 | - | -$14.21 M(+32.1%) | -$45.49 M(+8.6%) |
| Mar 2018 | - | -$10.76 M(+0.3%) | -$41.90 M(+3.3%) |
| Dec 2017 | -$40.55 M(+26.3%) | -$10.72 M(+9.4%) | -$40.55 M(+6.9%) |
| Sept 2017 | - | -$9.80 M(-7.7%) | -$37.94 M(+1.0%) |
| June 2017 | - | -$10.62 M(+12.9%) | -$37.55 M(+2.8%) |
| Mar 2017 | - | -$9.40 M(+15.9%) | -$36.53 M(+13.8%) |
| Dec 2016 | -$32.10 M(+103.9%) | -$8.12 M(-13.7%) | -$32.10 M(+33.8%) |
| Sept 2016 | - | -$9.41 M(-2.0%) | -$23.99 M(+64.5%) |
| June 2016 | - | -$9.60 M(+92.7%) | -$14.58 M(+192.7%) |
| Mar 2016 | - | -$4.98 M | -$4.98 M |
| Dec 2015 | -$15.75 M | - | - |
FAQ
- What is Kala Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Kala Pharmaceuticals?
- What is Kala Pharmaceuticals annual EBITDA year-on-year change?
- What is Kala Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Kala Pharmaceuticals?
- What is Kala Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Kala Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Kala Pharmaceuticals?
- What is Kala Pharmaceuticals TTM EBITDA year-on-year change?
What is Kala Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of KALA is -$36.08 M
What is the all time high annual EBITDA for Kala Pharmaceuticals?
Kala Pharmaceuticals all-time high annual earnings before interest, taxes, depreciation & amortization is -$15.75 M
What is Kala Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, KALA annual earnings before interest, taxes, depreciation & amortization has changed by +$937.00 K (+2.53%)
What is Kala Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of KALA is -$7.47 M
What is the all time high quarterly EBITDA for Kala Pharmaceuticals?
Kala Pharmaceuticals all-time high quarterly earnings before interest, taxes, depreciation & amortization is $30.67 M
What is Kala Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, KALA quarterly earnings before interest, taxes, depreciation & amortization has changed by -$306.00 K (-4.27%)
What is Kala Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of KALA is -$32.91 M
What is the all time high TTM EBITDA for Kala Pharmaceuticals?
Kala Pharmaceuticals all-time high TTM earnings before interest, taxes, depreciation & amortization is -$2.34 M
What is Kala Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, KALA TTM earnings before interest, taxes, depreciation & amortization has changed by +$7.27 M (+18.10%)